Lipum has submitted an international patent application for SOL-116 as a treatment for inflammation-driven cancer. The patent application is based on the company's research demonstrating that SOL-116 inhibits the growth of cancer cells by blocking the target protein BSSL. Additionally, studies on breast cancer patients indicate that high expression of BSSL correlates with a poor prognosis and shorter survival.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/04/lipum-seeks-patent-protecting-inflammation-driven-cancer-treatment/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/lipum-ab/r/biostock--lipum-seeks-patent-protecting-inflammation-driven-cancer-treatment,c3955717

(c) 2024 Cision. All rights reserved., source Press Releases - English